CYTK stock forecast
Our latest prediction for Cytokinetics, Inc.'s stock price was made on the Jan. 15, 2020 when the stock price was at 12.69$.
In the short term (2weeks), CYTK's stock price should underperform the market by -5.43%. During that period the price should oscillate between -9.60% and +9.99%.
In the medium term (3months), CYTK's stock price should underperform the market by -12.79%. During that period the price should oscillate between -38.21% and +23.47%.Get email alerts
About Cytokinetics, Inc.
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
At the moment the company generates 31M USD in revenues.
On its last earning announcement, the company reported a loss of -2.08$ per share.
The book value per share is 1.37$
Three months stock forecastJan. 15, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|